Personal CFO Solutions’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $557K | Hold |
62,188
| – | – | 0.1% | 198 |
|
|
2025
Q1 | $466K | Buy |
62,188
+672
| +1% | +$5.04K | 0.09% | 218 |
|
|
2024
Q4 | $463K | Sell |
61,516
-215
| -0.3% | -$1.62K | 0.09% | 219 |
|
|
2024
Q3 | $469K | Hold |
61,731
| – | – | 0.07% | 278 |
|
|
2024
Q2 | $381K | Sell |
61,731
-5,000
| -7% | -$30.9K | 0.06% | 315 |
|
|
2024
Q1 | $339K | Buy |
66,731
+428
| +0.6% | +$2.17K | 0.05% | 361 |
|
|
2023
Q4 | $397K | Sell |
66,303
-453
| -0.7% | -$2.71K | 0.07% | 293 |
|
|
2023
Q3 | $473K | Hold |
66,756
| – | – | 0.09% | 205 |
|
|
2023
Q2 | $470K | Sell |
66,756
-1,000
| -1% | -$7.04K | 0.1% | 214 |
|
|
2023
Q1 | $565K | Buy |
67,756
+366
| +0.5% | +$3.05K | 0.12% | 172 |
|
|
2022
Q4 | $774K | Hold |
67,390
| – | – | 0.16% | 118 |
|
|
2022
Q3 | $849K | Buy |
67,390
+302
| +0.5% | +$3.81K | 0.21% | 88 |
|
|
2022
Q2 | $710K | Sell |
67,088
-42,100
| -39% | -$446K | 0.17% | 109 |
|
|
2022
Q1 | $1.78M | Hold |
109,188
| – | – | 0.35% | 48 |
|
|
2021
Q4 | $1.51M | Hold |
109,188
| – | – | 0.28% | 64 |
|
|
2021
Q3 | $1.57M | Sell |
109,188
-2,490
| -2% | -$35.8K | 0.32% | 58 |
|
|
2021
Q2 | $1.77M | Sell |
111,678
-10,000
| -8% | -$158K | 0.36% | 54 |
|
|
2021
Q1 | $1.24M | Buy |
121,678
+16,500
| +16% | +$168K | 0.27% | 73 |
|
|
2020
Q4 | $784K | Buy |
105,178
+14,000
| +15% | +$104K | 0.19% | 106 |
|
|
2020
Q3 | $0 | Buy |
91,178
+8,500
| +10% | – | ﹤0.01% | 155 |
|
|
2020
Q2 | $394K | Sell |
82,678
-4,400
| -5% | -$21K | 0.12% | 164 |
|
|
2020
Q1 | $174K | Buy |
87,078
+55,078
| +172% | +$110K | 0.06% | 249 |
|
|
2019
Q4 | $110K | Buy |
+32,000
| New | +$110K | 0.03% | 330 |
|